Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 8DNSP-11 (Dopamine Neuron Stimulating Peptide-11) literatureeuropepmc · Observational · Preclinical2013

Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro.

DNSP-11 treatment increased potassium-evoked dopamine release in certain striatal subregions at two weeks, but overall dopamine release remained unchanged, indicating limited clinical relevance.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the dnsp-11 (dopamine neuron stimulating peptide-11) corpus
1
Preclinical
7
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

The study investigated the effects of a single treatment of dopamine neuron stimulating peptide-11 (DNSP-11) on dopamine neuron function in rats. The treatment was delivered to the substantia nigra, and dopamine release was measured four weeks post-treatment. No significant changes in dopamine release were observed, although potassium-evoked dopamine release was increased in specific striatal subregions at two weeks.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.Preclinical2013

Abstract

The authors’ words, as europepmc supplied them

Glial cell-line derived neurotrophic factor (GDNF) has demonstrated robust effects on dopamine (DA) neuron function and survival. A post-translational processing model of the human GDNF proprotein theorizes the formation of smaller, amidated peptide(s) from the proregion that exhibit neurobiological function, including an 11-amino-acid peptide named dopamine neuron stimulating peptide-11 (DNSP-11). A single treatment of DNSP-11 was delivered to the substantia nigra in the rat to investigate effects on DA-neuron function. Four weeks after treatment, potassium (K+) and D-amphetamine evoked DA release were studied in the striatum using microdialysis. There were no significant changes in DA-release after DNSP-11 treatment determined by microdialysis. Dopamine release was further examined in discrete regions of the striatum using high-speed chronoamperometry at 1-, 2-, and 4-weeks after DNSP-11 treatment. Two weeks after DNSP-11 treatment, potassium-evoked DA release was increased in specific subregions of the striatum. However, spontaneous locomotor activity was unchanged by DNSP-11 treatment. In addition, we show that a single treatment of DNSP-11 in the MN9D dopaminergic neuronal cell line results in phosphorylation of ERK1/2, which suggests a novel cellular mechanism responsible for increases in DA function.

Background

This paper addresses the modulation of dopamine neuron function, which is critical in various neurological conditions. Previous research has indicated that dopamine signaling is essential for numerous brain functions, and alterations in this signaling pathway can lead to disorders. Understanding how DNSP-11 affects dopamine neurons may provide insights into potential therapeutic avenues.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Increased ERK 1/2 phosphorylation observed in vitro, specific numeric values not reported.
  • Not reported in abstract.

Limitations

  • Specific numeric findings not reported.
  • Lack of detail on study design and population.

Elsewhere in the DNSP-11 (Dopamine Neuron Stimulating Peptide-11) corpus

BIdentification of novel GDNF isoforms and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease.europepmc · 2011 · Mature GDNF peptide down-regulated in AD patients compared to normal controls.HumanCA synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.europepmc · 2013 · Approximately 66% increase in extracellular DA levels compared to vehicle.AnimalCMethodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease.europepmc · 2015 · 300μg DNSP-11 increased dopamine turnover in striatum and substantia nigra in normal rats over 3 weeks.AnimalCMethodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques.europepmc · 2018 · Not reported in abstract.AnimalCSpatial and temporal immunoreactivity in the rat brain using an affinity purified polyclonal antibody to DNSP-11.europepmc · 2019 · Not reported in abstract.AnimalBNovel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer's Disease and Inhibitors of Amyloid Formation.europepmc · 2023 · hIAPPβ was significantly reduced in the plasma of AD patients with an accuracy of 89%.Human